Study | Study design | Participants | Sample size (M/F) | Intervention/control a | Outcomes |
---|---|---|---|---|---|
Yao et al. | Cohort study | 45–75 years old (mean: 63); all patients with SqCC; stage III B 20 cases/stage IV 51 cases | 71 (69/2); CIV: 48 (47/1); IIV: 23 (22/1) | CIV: Endostar by infusion pump (15 mg/d, 11 ml/h) from day 0 to 8, combined with GP chemotherapy (gemcitabine and cisplatin); IIV: Endostar by intravenous infusion (15 mg/d, 4 h/d) from day 0 to 13, combined with GP chemotherapy (gemcitabine and cisplatin) | Efficacy: OS, PFS, ORR, DCR; safety: leukopenia, neutropenia, thrombocytopenia, anemia, hyponatremia, Transaminase elevation, laryngeal hemorrhage, hypertension, fatigue, nausea & vomiting, constipation, diarrhea, papule, purulent herpes, fever, thromboembolism |
Li et al. | Cohort study | 41–70 years old; all patients with NSCLC; stage III B 34 cases/stage IV 82 cases | 116 (77/39); CIV: 58 (40/18); IIV: 58 (37/21) | CIV: Endostar by mini-osmotic pump (210 mg, 5 ml/h) from day 1 to 10, combined with docetaxel, gemcitabine, pemetrexed, cisplatin, nedaplatin, etc.; IIV: Endostar by intravenous infusion (15 mg/d, 4 h/d) from day 1 to 14, combined with docetaxel, gemcitabine, pemetrexed, cisplatin, nedaplatin, etc. | Efficacy: OS, PFS, ORR, DCR; safety: neutropenia, anemia, thrombocytopenia, hemorrhage, nausea & vomiting, mucositis, constipation, diarrhea, transaminase elevation, total bilirubin elevation, blood creatinine elevation, fever, rash, fatigue, pain, allergy, peripheral neurotoxicity, alopecia, arrhythmia |
Cheng et al. | Cohort study | 33–78 years old (mean: 59.5); SqCC 21 cases/ADC: 36 cases/other types 12 cases; stage III 7 cases/stage IV 54 cases/postoperative recurrence 8 cases | 69 (50/19); CIV: 20 (13/7); IIV: 49 (37/12) | CIV: Endostar by mini-osmotic pump (105 mg/m2, 10 ml/h) from day 1 to 5, combined with first-line chemotherapy (gemcitabine and platinum, pemetrexed and platinum, or paclitaxel and platinum); IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 4 h/d) from day 1 to 14, combined with first-line chemotherapy (gemcitabine and platinum, pemetrexed and platinum, or paclitaxel and platinum) | Efficacy: PFS, ORR, DCR; safety: Neutropenia, anemia, thrombocytopenia, arrhythmia, myocardial ischemia, neurotoxicity, rash, transaminase elevation, vomiting, infection, nausea, deep vein thrombosis, hemorrhage |
Zhu et al. | Cohort study | 33–75 years old (median: 58); SqCC 16 cases/ADC 45 cases/other types 3 cases; all patients with advanced NSCLC | 64 (46/18); C: 33; IIV: 31 | CIV: Endostar by infusion pump (210 mg, 3 ml/h) from day 1 to 7, combined with AP chemotherapy (pemetrexed and cisplatin) or TP (paclitaxel and cisplatin); IIV: Endostar by intravenous infusion (15 mg/d, 4 h/d) from day 1 to 14, combined with AP chemotherapy (pemetrexed and cisplatin) or TP (paclitaxel and cisplatin) | Efficacy: PFS, ORR, DCR; safety: myelosuppression, liver dysfunction, gastrointestinal reaction, cardiovascular toxicity, peripheral neurotoxicity, hemoptysis |
Pang et al. | RCT | 41–76 years old (mean: 61); SqCC 33 cases/ADC 45 cases/AdSqCC 3 cases/LCC 3 cases; stage III B 32 cases/stage IV 52 cases | 84 (48/36); CIV: 42 (23/19); IIV: 42 (25/17) | CIV: Endostar by infusion pump (7.5 mg/m2/d, 5 ml/h) from day 1 to 7, combined with GP chemotherapy (gemcitabine and cisplatin); IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 3–4 h/d) from day 1 to 14, combined with GP chemotherapy (gemcitabine and cisplatin) | Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, nausea & vomiting, liver dysfunction, neurotoxicity, fatigue, diarrhea |
Wen and Chen | RCT | 24–76 years old (median: 58); SqCC 39 cases/ADC 28 cases/AdSqCC 4 cases; stage III B 48 cases/stage IV 23 cases; initial treatment 46 cases/retreatment 25 cases | 71 (45/26); CIV: 37; IIV: 34 | CIV: Endostar by infusion pump (7.5 mg/m2/d, 10 ml/h) from day 1 to 14, combined with TC chemotherapy (paclitaxel and carboplatin); IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 3–4 h/d) from day 1 to 14, combined with TC chemotherapy (paclitaxel and carboplatin) | Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, nausea & vomiting, alopecia, muscle & joint soreness |
Kahaerjiang et al. | NRCT | 34–75 years old (median: 51.5); SqCC 16 cases/ADC 12 cases; stage III 12 cases/stage IV 16 cases | 28 (20/8); CIV: 14; IIV: 14 | CIV: Endostar by infusion pump (225 mg, 2 ml/h) from day 1 to 15, combined with NP chemotherapy (vinorelbine and cisplatin); IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 3–4 h/d) from day 1 to 14, combined with NP chemotherapy (vinorelbine and cisplatin) | Efficacy: ORR, DCR; safety: leukopenia, neutropenia, anemia, nausea & vomiting, cardiovascular toxicity |
Tang et al. | NRCT | 26–78 years old; all patients with advanced NSCLC | 54 (34/20); CIV: 28; IIV: 26 | CIV: Endostar by intravenous infusion (7.5 mg/m2, 4 h) on day 1, Endostar by infusion pump (195 mg, 1.8 ml/h) from day 2 to 8, combined with GP chemotherapy (gemcitabine and cisplatin); IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 4 h/d) from day 1 to 14, combined with GP chemotherapy (gemcitabine and cisplatin) | Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, nausea & vomiting, alopecia |
Meng | NRCT | 25–70 years old (mean: 57); all patients with stage IV NSCLC | 40 (28/12); CIV: 20 (13/7); IIV: 20 (15/5) | CIV: Endostar by intravenous infusion (7.5 mg/m2, 4 h) on day 1, Endostar by infusion pump (195 mg, 1.8 ml/h) from day 2 to 8, combined with GP chemotherapy (gemcitabine and cisplatin); IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 4 h/d) from day 1 to 14, combined with GP chemotherapy (gemcitabine and cisplatin) | Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, gastrointestinal reaction |